

Title (en)  
SPHINGOSINE KINASE INHIBITORS

Title (de)  
INHIBITOREN DER SPHINGOSINKINASE

Title (fr)  
INHIBITEURS DE LA SPHINGOSINE KINASE

Publication  
**EP 2513066 A1 20121024 (DE)**

Application  
**EP 10781837 A 20101118**

Priority  
• EP 09015631 A 20091217  
• EP 2010007003 W 20101118  
• EP 10781837 A 20101118

Abstract (en)  
[origin: WO2011082732A1] The invention relates to compounds of formula (I), where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, M1, M2, M3, M4, Y1, Y2, V, W, n, m and o have the meanings specified herein, and to the physiologically compatible salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including the mixtures thereof in all ratios, for use in the treatment of diseases that are influenced by inhibiting sphingosine kinase 1.

IPC 8 full level  
**C07D 249/06** (2006.01); **A61K 31/4192** (2006.01); **A61K 31/421** (2006.01); **A61K 31/4245** (2006.01); **A61K 31/425** (2006.01); **A61P 1/00** (2006.01); **A61P 9/00** (2006.01); **A61P 11/00** (2006.01); **A61P 13/00** (2006.01); **A61P 17/00** (2006.01); **C07D 263/32** (2006.01); **C07D 277/28** (2006.01); **C07D 277/40** (2006.01); **C07D 417/04** (2006.01); **C07D 417/14** (2006.01)

CPC (source: EP KR US)  
**A61K 31/427** (2013.01 - KR); **A61P 1/00** (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 1/16** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 5/14** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 13/00** (2017.12 - EP); **A61P 13/08** (2017.12 - EP); **A61P 13/10** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 15/00** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/02** (2017.12 - EP); **A61P 17/10** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 27/02** (2017.12 - EP); **A61P 27/06** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 249/06** (2013.01 - EP US); **C07D 263/32** (2013.01 - EP US); **C07D 277/28** (2013.01 - EP US); **C07D 277/40** (2013.01 - EP US); **C07D 413/04** (2013.01 - KR); **C07D 417/04** (2013.01 - EP KR US); **C07D 417/14** (2013.01 - EP US)

Citation (search report)  
See references of WO 2011082732A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2011082732 A1 20110714**; AR 079483 A1 20120125; AU 2010341229 A1 20120802; BR 112012014884 A2 20160322; CA 2784647 A1 20110714; CN 102639513 A 20120815; EA 201200875 A1 20130130; EP 2513066 A1 20121024; IL 220188 A0 20120731; JP 2013514287 A 20130425; KR 20120096076 A 20120829; MX 2012006962 A 20120717; SG 181643 A1 20120730; US 2012252815 A1 20121004; US 8907098 B2 20141209; ZA 201205277 B 20130424

DOCDB simple family (application)  
**EP 2010007003 W 20101118**; AR P100104661 A 20101215; AU 2010341229 A 20101118; BR 112012014884 A 20101118; CA 2784647 A 20101118; CN 201080055098 A 20101118; EA 201200875 A 20101118; EP 10781837 A 20101118; IL 22018812 A 20120605; JP 2012543496 A 20101118; KR 20127018192 A 20101118; MX 2012006962 A 20101118; SG 2012042958 A 20101118; US 201013516370 A 20101118; ZA 201205277 A 20120716